Adebrelimab - Atridia
Alternative Names: HTI-1088; HTI-1316; SHR 1316Latest Information Update: 22 Jul 2024
At a glance
- Originator Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute
- Developer Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute; Sheng Jing Hospital; Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Small cell lung cancer
- Phase III Non-small cell lung cancer
- Phase II Cervical cancer; Oesophageal cancer
- Phase I Solid tumours
- Clinical Phase Unknown Breast cancer
- No development reported Cancer; Haematological malignancies
Most Recent Events
- 20 Jun 2024 Shanghai Hengrui Pharmaceutical initiates phase-I/II clinical trials in Oesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT06474468)
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 01 Apr 2024 Jiangsu Hengrui Medicine plans a phase II trial for Breast cancer (Combination therapy, Neoadjuvant therapy, First-line therapy, In adults, In the elderly) in China (IV, Injection) in April 2024 (NCT06340230)